Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke

Cognitive Impairment Clinical Trial

Official title:

Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke and Its Mechanism of Brain Electricity and Brain Metabolism

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06344390
• Other study ID #: 20210327
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 10, 2024
• Est. completion date: December 31, 2024

Study information

• Verified date: March 2024
• Source: The First Hospital of Hebei Medical University
• Contact: Bing Han, Ph.D. degree
• Phone: 13784333398
• Email: Hanbing1987[@]hebmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke.

Description:

Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 31, 2024
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Han Chinese, age 40-80 years old, male and female, right-handed;

• The diagnosis is consistent with the Expert Consensus on the Management of Cognitive Impairment after Stroke 2021;

• NIHSS score 1-15 points;

• Daily Living Ability Scale (ADL) =75 score;

• The Informed consent signed by the patient or his legal representative

Exclusion Criteria:

• Can not cooperate with the examination (including neuropsychological tests and scale assessment);

• There were memory disorders, dementia with lewy bodies and frontotemporal dementia before the onset of stroke events;

• There were definite infectious diseases 2 weeks before admission; Have a serious mental illness, previous history of cancer, alcohol or drug abuse;

• Use of drugs that may affect cognitive function, including sedatives, anti-anxiety drugs, hypnotics, nootropic drugs, and cholinoid drugs;

• Can not accept brain MRI examination

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Cognitive Impairment
• Ischemic Stroke

Intervention

Drug:
• Pentoxifylline
Take pentoxifylline 0.4 g twice daily

Locations

Country	Name	City	State
China	BHan	Shijiazhuang

Sponsors (1)

Lead Sponsor	Collaborator
The First Hospital of Hebei Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pentoxifylline can improve cognitive impairment after ischemic stroke	The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment.If the score is less than 26 points, it is considered to have cognitive impairment.Patient scores get higher after 3 months, we think pentoxifylline can improve cognitive impairment after ischemic stroke.	3 months